Rite Aid — Controlled Substance Dispensing
Rite Aid Resolves Allegations Over Opioid Dispensing Practices
Source: U.S. Department of Justice
TL;DR: Rite Aid Resolves Allegations Over Opioid Dispensing Practices This case resulted in a Bankruptcy Resolution resolution and demonstrates the impact of whistleblower protections in recovering funds from fraud.
Summary
Rite Aid Corporation and affiliated entities agreed to resolve DOJ allegations under the False Claims Act and the Controlled Substances Act tied to opioid dispensing practices. DOJ alleged that, from May 2014 through June 2019, Rite Aid pharmacies dispensed large volumes of controlled-substance prescriptions that lacked a legitimate medical purpose, were medically unnecessary, or were otherwise invalid, including high-risk combinations (such as "the trinity") and excessive opioid quantities. The government also alleged Rite Aid filled prescriptions despite clear warning signs, including internal concerns raised by pharmacists and internal notes about suspicious prescribers. The resolution included a cash payment and an allowed unsecured claim in Rite Aid's bankruptcy, and DOJ noted a Corporate Integrity Agreement with HHS-OIG including independent prescription-claims review.
Our Take
Retail pharmacy controlled-substance cases tend to be operational, not abstract: what the verification workflow looked like, how "red flags" were captured (or overridden), and whether corporate systems made it easier to dispense than to pause. Insiders often have the most useful evidence: pharmacist escalation logs, prescriber "do-not-fill" notes, communications about quotas or customer pressure, and records showing how exceptions were normalized across stores. Patterns matter—repeat prescribers, repeat drug combinations, repeat overrides—because they show what the organization treated as routine rather than aberrational.
Read the full article from the original source:
View Original ArticleOpens in a new tab. Content from U.S. Department of Justice.
Notice
The summaries above are based on publicly available information released by the U.S. Department of Justice and are provided for informational purposes only. They do not constitute legal advice, investigative findings, or allegations by Disclosure Strategy. Our commentary reflects general, experience-based observations about how False Claims Act matters commonly arise and is not a statement about any party's liability.